Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE-003 in metastatic squamous non-small cell lung cancer after PD-1/PD-L1 inhibitor progression
NL-OMON59438Phase 3Active, not recruiting
- Sponsor
- OncoC4
- Start
- Apr 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of gotistobart and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OncoC4. Primary endpoint: Overall survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
gotistobartdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59438.